ABIONYX Pharma, winner of the France 2030 Plan’s “i-Démo” call for projects, awarded €8.7 million from the French government to fight against Sepsis, the 3rd leading cause of death worldwide

ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant apoA-I, announces today that its clinical development in sepsis has been selected as part of the “i-Démo” call for projects under the France 2030 plan, operated by Bpifrance on behalf of the French government.

After 6 months of examining ABIONYX Pharma’s CER-001 Sepsis project, a panel of experts was able to validate and objectify the quality of the project in its scientific, technological and clinical aspects.

The CER-001 Sepsis project represents a strategic cornerstone for ABIONYX Pharma, leveraging its unique expertise to use the only recombinant apoA-I protein in the treatment of the most severe inflammation in the human body.

The ABIONYX Pharma Sepsis project currently operates on two strategic fronts:

1. An integrated biomedicine approach: ABIONYX Pharma develops a combined bioproduction/biotherapy approach secured by proprietary patents until 2042 along the entire chain.
2. An innovative clinical strategy: circulating apoA-I collapses in situations of severe inflammation. Supplementation with recombinant human apoA-I in these critical situations enables to treat all types of patients, even immuno-depressed patients. Based on the very positive Phase 2a clinical results, the Phase 2b/3 study between the United States and Europe aims to confirm a significant reduction in mortality.

ABIONYX Pharma is the world leader in recombinant apoA-I, the result of 20 years of expertise and innovation in lipid metabolism, bioproduction and the clinical development of this unique bioproduct. With its exceptional know-how, ABIONYX Pharma demonstrated the safety, efficacy and therapeutic potential of apoA-I in critical indications, particularly in LCAT deficiency, a rare disease, and is now exploring the most severe inflammatory diseases such as cytokine storms and severe inflammation in ophthalmology and neurology.

Access here the full press release

View source version on businesswire.com: https://www.businesswire.com/news/home/20250219591056/en/